Oncoinvent ASA (FRA:7BG)

Market Cap	19.79M
Revenue (ttm)	2.37M +246.4%
Net Income	-13.10M
EPS	-0.11
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	29
Open	4.320
Previous Close	4.330
Day's Range	4.320 - 4.320
52-Week Range	0.000 - 9.040
Beta	n/a
RSI	57.12
Earnings Date	Apr 22, 2026

About Oncoinvent ASA

Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. The company is based in Oslo, Norway.

• Industry: Biological Products, Except Diagnostic Substances
• CEO: Oystein Soug
• Employees: 36
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 7BG

Financial Performance

In 2025, Oncoinvent ASA's revenue was 28.07 million, an increase of 246.40% compared to the previous year's 8.10 million. Losses were -155.07 million, 10.6% more than in 2024.

Financial numbers in NOK